Amphastar Pharmaceuticals (AMPH) Raw Materials (2015 - 2026)

Amphastar Pharmaceuticals has reported Raw Materials for 12 years, with the latest figure at $105.5 million in Q2 2026.

• On a quarterly basis, Raw Materials fell 0.98% year-over-year to $105.5 million in Q2 2026; TTM through Jun 2026 was $105.5 million, a 0.98% decrease from a year earlier, with the FY2025 full-year figure at $106.8 million, up 31.06% from the prior year.
• Raw Materials was $105.5 million for Q2 2026 at Amphastar Pharmaceuticals, up from $104.7 million in the prior quarter.
• The five-year high for Raw Materials was $106.8 million in Q4 2025, with the low at $40.4 million in Q1 2022.
• Average Raw Materials over 5 years is $70.0 million, with a median of $55.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Raw Materials decreased 6.7% in 2022, then soared 100.84% in 2025.
• Over 5 years, Raw Materials stood at $47.6 million in 2022, then increased by 5.2% to $50.1 million in 2023, then surged by 62.76% to $81.5 million in 2024, then soared by 31.06% to $106.8 million in 2025, then dropped by 1.25% to $105.5 million in 2026.
• The last three Raw Materials figures came in at $105.5 million (Q2 2026), $104.7 million (Q1 2026), and $106.8 million (Q4 2025), per Business Quant data.